The North America Rapid Microbiology Testing Market is witnessing robust growth driven by rising prevalence of infectious diseases, technological advancements, and strict regulatory standards for food and pharmaceutical safety. The market size was valued at USD 2,600 Million in 2025 and is projected to reach USD 6,890 Million by 2035, growing at a CAGR of 9.3% from 2024 to 2035.
The economic impact of tariffs on "North America Rapid Microbiology Testing Market".
Market Growth Drivers
Rising Incidence of Infectious Diseases: Increased incidences of infectious diseases and food-borne illnesses in North America have fueled the demand for rapid microbiology testing. For example, BD (Becton, Dickinson and Company) has expanded its BD MAX™ System offerings to include new panels for respiratory and gastrointestinal pathogens, improving detection speed and accuracy. The urgency for quick and accurate diagnostics is particularly high in clinical settings, with hospitals and public health labs striving to identify outbreaks early and prevent widespread transmission.
Advancements in Testing Technologies: Technological innovations such as automated systems, PCR-based identification, and next-generation sequencing are reducing turnaround times and increasing test throughput. Thermo Fisher Scientific recently introduced advanced platforms like the SureTect™ PCR System, enabling simultaneous identification of multiple pathogens. These improvements are making rapid microbiology tests more accessible and reliable, leading to their broader adoption in pharmaceuticals, food and beverage, and healthcare industries.
Market Trends
Adoption of Point-of-Care (POC) Testing: There is a marked trend toward the adoption of point-of-care microbiology testing in North America. This approach enables healthcare providers to diagnose infections more quickly, reducing the time to treatment. Abbott, for example, expanded its ID NOW™ molecular platform to offer rapid detection for COVID-19 and other pathogens at the point of care. This trend is particularly significant in rural and remote areas, where laboratory infrastructure may be limited.
Integration with Digital Health Platforms: The integration of rapid microbiology testing devices with digital health platforms and laboratory information management systems (LIMS) is enhancing data management and remote monitoring capabilities. Companies like BioMérieux have developed systems that sync seamlessly with hospital LIMS, providing real-time updates and facilitating rapid epidemiological surveillance.
Market Opportunities
Expansion in Food Safety Applications: The growing demand for rapid microbiology testing in the food and beverage industry to comply with stringent regulatory standards is a major opportunity. For example, 3M Food Safety has introduced kits that enable high-throughput pathogen detection, helping manufacturers meet safety and quality guidelines efficiently.
Pharmaceutical Industry Compliance: Increasing regulatory requirements for contamination control in pharmaceutical manufacturing are driving opportunities for rapid testing solutions. Companies like Merck KGaA are investing in rapid sterility testing methods to accelerate batch release times and production efficiency.
North America Rapid Microbiology Testing Market Revenue (USD Million), 2020-2035
The market revenue for rapid microbiology testing in North America demonstrates strong and consistent growth from 2020 to 2035. Starting at USD 1,150 Million in 2020, the market sees a steady upward trend as demand rises across healthcare, pharmaceutical, and food sectors. Growth accelerates after 2025 owing to wider adoption of advanced testing platforms and regulatory drives. By 2030, the revenue almost doubles, reaching USD 4,330 Million, and is projected to hit USD 6,890 Million by 2035. This trajectory reflects increasing investments in infection control and innovation in rapid diagnostics, which substantially reduce detection time and improve patient outcomes.
North America Rapid Microbiology Testing Market by Regional Share (%), 2025
In 2025, the United States leads the North American market for rapid microbiology testing, holding a dominant 78% share owing to its advanced healthcare infrastructure, higher testing rates, and robust investment in R&D. Canada follows with 14% market share, supported by growing adoption in clinical and food safety applications. Mexico holds 5%, reflecting its expanding pharmaceutical industry and rising food safety standards. The remaining 3% is distributed among other regions, reflecting gradual but promising market penetration. The chart underlines the significant contribution of the US market and the emerging potential in other North American countries.
Recent Developments
In March 2024, Thermo Fisher Scientific introduced the RapidFinder™ Pathogen Detection Assay, which utilizes multiplex PCR to simultaneously detect multiple bacteria, viruses, and yeasts. The solution is aimed at food and beverage manufacturers seeking compliance with strict North American regulatory standards. This product launch enhances rapid response capabilities and minimizes the risk of contamination-related recalls.
In May 2024, BD (Becton, Dickinson and Company) announced the launch of its BD Veritor™ Plus System with COVID-19 and Influenza A+B combination testing. This development offers faster diagnostic results at the point of care, allowing healthcare providers to efficiently triage and treat patients during peak respiratory seasons. The system’s integration with digital health records streamlines data entry and reporting.
In February 2024, BioMérieux expanded its ETEST™ line for antimicrobial susceptibility testing with a focus on rapid results for multidrug-resistant organisms. The new panels were introduced across leading laboratories in the US and Canada, enabling clinicians to make informed treatment decisions and supporting the containment of healthcare-associated infections.
Press Releases